We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Riverside Medical Practice
GPs Prescribing Mounjaro
An Update On Weight Loss Medication, Tirzepatide 23rd June 2025
NHS England and NICE have approved the use of Tirzepatide, which you may also know as Mounjaro or ‘the weight loss drug’, from primary care. You may well hear that Tirzepatide is available from primary care from 23rd June 2025. However, in the first two years entry criteria have been set by NHS England to a very small number of people. This is to allow safe entry of this repurposed medicine into the health system.
Please only contact us if you are eligible, this means you have a BMI of 40 or higher and at least four of these additional conditions, which will already have been diagnosed by your GP or another medical professional:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Type 2 diabetes mellitus
Published: Jun 25, 2025